Raymond James & Associates’s Juno Therapeutics, Inc. JUNO Stock Holding History

Raymond James & Associates’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-50,718	Closed	-$2.32M	–	3661
2017 Q4	$2.32M	Buy	50,718 +41,381	+443%	+$2.06M	﹤0.01%	1596
2017 Q3	$419K	Buy	+9,337	New	+$318K	﹤0.01%	2587
2016 Q3	–	Sell	-5,839	Closed	-$224K	–	3347
2016 Q2	$224K	Sell	5,839 -950	-14%	-$39.4K	﹤0.01%	2587
2016 Q1	$259K	Buy	+6,789	New	+$237K	﹤0.01%	2430

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Raymond James & Associates's JUNO Position: Q1 2018 in Review

Raymond James & Associates sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 50,718 shares — an estimated $2.32M sold.

Raymond James & Associates first reported a position in JUNO in Q1 2016 and held it in 4 quarters. The position peaked at $2.32M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Raymond James & Associates reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Raymond James & Associates sold 50,718 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $2.32M.
Raymond James & Associates first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 4 quarters.
Raymond James & Associates's Juno Therapeutics, Inc. position peaked at $2.32M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.